DARZALEX 20 mg/mL concentrate for solution for infusion.
*Company:
Janssen Sciences Ireland (a Johnson & Johnson Company)Status:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 24 October 2024
File name
EN-IE-Darzalex IV-20241021-PIL-II-072-clean-approved_EDMS-ERI-78724632_104.0.pdf
Reasons for updating
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
EMEA/H/C/004077/II/0072: Type II variation, indication extension (D-VRd in NDMM) based on the PERSEUS study. The indication extension impacted the SC formulation only but there was a small administrative update to the PIL for the IV formulation; at the end of the document the EMA website address was changed from: http://www.ema.europa.eu to https://www.ema.europa.eu. The date of revision was also updated.
Updated on 16 October 2024
File name
EN-IE-Darzalex IV-20240919-SmPC-II-074-clean-approved_EDMS-ERI-78724632_102.0.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
EMEA/H/C/004077/II/0074: Provision of the final CSR of study MMY3008 (MAIA)
Updated on 20 March 2024
File name
EN-Darzalex IV-20240215-SPC-II-070-clean-approved_EDMS-RIM-1256104_2.0.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
II/070: CCDS update MMY3007 Final OS analysis
Updated on 15 November 2023
File name
SPC-Darzalex_IE-UK(NI)_EN_Type IB_069_IV Formulation 20mg-mL_20mL and 5mL_Shelf Life Extension_Clean.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
6.3 Shelf life
Unopened vials
23 years.
10. DATE OF REVISION OF THE TEXT
14 November 2023
Updated on 03 November 2023
File name
Clean EN-PIL-IE -IV 20mg MI and Ocular Darzalex with GEN 2 -049.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 6 - what the product contains
Updated on 03 November 2023
File name
Clean SmPC IE 20mg IV MI and Ocular with GEN 2-049-.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.1 - List of excipients
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 24 March 2023
File name
EN-IE -IV 20mg MI and Ocular Darzalex-20230209-II-063-064-clean-adjusted-without-II-049 .pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
Updated to add Myocardial Infarction and Ocular events as signs/symptoms of Infusion Related Reactions.
Updated on 24 March 2023
File name
SmPC 20mg IV MI and Ocular EN-Darzalex-20230209-063-064-clean-adjusted-without-II-049.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated to add Myocardial Infarction and Ocular events as signs/symptoms of Infusion Related Reactions.
- SmPC Section 4.4 and 4.8 impacted.
Updated on 16 January 2023
File name
IE_NI - SPC IV - Addition of COVID-19 as an ADR.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 16 January 2023
File name
IE_NI-Patient Information Leaflet IV - Addition of COVID-19 as an ADR.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 25 July 2022
File name
Darzalex IV - consolidated changes from 060 and 061.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
EMA/H/C/4077/II/060/G - Final OS data from studies MMY3003 and MMY3004 resulting in update to section 5.1
EMEA/H/C/004077/IB/061/G - CMC - ATC code + shelf life SC to 2 years - resulting in update to Section 5.1 and Section 6.3 (SC formulation only)
Updated on 09 June 2022
File name
Clean Darzalex RMP HCP Card black triangle update.pdf
Reasons for updating
- Replace File
Free text change information supplied by the pharmaceutical company
Removal of Black Triangle
Updated on 09 June 2022
File name
Clean Patient Card - Darzalex black triangle update.pdf
Reasons for updating
- Replace File
Free text change information supplied by the pharmaceutical company
Removal of Black Triangle
Updated on 09 June 2022
File name
Clean Darzalex RMP Blood Lab Card - black triangle update.pdf
Reasons for updating
- Replace File
Free text change information supplied by the pharmaceutical company
Removal of Black Triangle
Updated on 25 March 2022
File name
IV Adjusted version - EN-Darzalex-IB-057-approved with II_53 revisions shown Clean.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Inclusion of updated efficacy data from Study MMY3008 in section 5.1 of the SmPC
Updated on 12 January 2022
File name
IE_NI-PIL-20 mg _mL_PIL - Jan 22 - EUPI-R-054-approved-adjusted-without-II-049.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 6 - date of revision
- Removal of Black Inverted Triangle
Free text change information supplied by the pharmaceutical company
Black triangle and explanatory text were removed from the SmPC and patient leaflet. QRD changes were made where applicable throughout the SmPC and patient leaflet
Updated on 12 January 2022
File name
IE_NI - 20 mg per ml - Jan 22 - EUPI-R-054-approved-adjusted-without-II-049.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
- Removal of Black Inverted Triangle
- Change to improve clarity and readability
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Black triangle and explanatory text were removed from the SmPC and patient leaflet. QRD changes were made where applicable throughout the SmPC and patient leaflet.
Updated on 08 December 2021
File name
Darzalex Patient Card CP-Updated.pdf
Reasons for updating
- Replace File
Free text change information supplied by the pharmaceutical company
Addition of AL amyloidosis
Updated on 08 December 2021
File name
Darzalex Blood Bank Card CP-Updated.pdf
Reasons for updating
- Replace File
Free text change information supplied by the pharmaceutical company
Addition of AL amyloidosis
Updated on 08 December 2021
File name
Darzalex HCP Card CP-Updated.pdf
Reasons for updating
- Replace File
Free text change information supplied by the pharmaceutical company
Addition of AL amyloidosis
Updated on 10 November 2021
File name
IRE & NI Darzalex-20 mg _mL_PIL- C15-050-051-CLEAN-adjusted-without-II-049.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 10 November 2021
File name
IE&NI_Darzalex 20 mg per mL SmPC C18-050-051-CLEAN-adjusted-without-II-049-07Oct21.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.8 Undesirable effects
Immune system disorders |
Hypogammaglobulinemiaa |
Common |
3 |
<1* |
Anaphylactic reactionb |
Rare |
- |
- |
5.1 Pharmacodynamic properties
With a median follow-up of 18.8 months, the primary analysis of PFS Results of a PFS analysis by censoring patients who were randomised to daratumumab maintenance in the second randomisation, at the date of the second randomisation showed HR=0.50; 95% CI: 0.34, 0.75; p=0.0005. Results of an updated PFS analysis with a median follow-up of 44.5 months, censoring patients who were randomised to daratumumab maintenance in the second randomisation, showed HR=0.43; 95% CI: 0.33, 0.55; p<0.0001. Median PFS was not reached in the D‑VTd arm and was 37.8 months in the VTd arm.
Updated on 28 June 2021
File name
IRE & NI Darzalex-20 mg _mL_PIL- C14_21June21_clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 24 June 2021
File name
IE&NI_Darzalex 20 mg per mL SmPC C17-43-44-clean-21June21.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
fainting added as common side effect
Updated on 24 June 2021
File name
IE&NI_Darzalex 20 mg per mL SmPC C17-43-44-clean-21June21.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
.2 Posology and method of administration
Table 1: DARZALEX dosing schedule in combination with lenalidomide and dexamethasone (Rd) (4-week cycle dosing regimen) and monotherapy |
|
Weeks |
Schedule |
Weeks 1 to 8 |
weekly (total of 8 doses) |
Weeks 9 to 24a |
every two weeks (total of 8 doses) |
Week 25 onwards until disease progressionb |
every four weeks |
a First dose of the every-2-week dosing schedule is given at Week 9 b First dose of the every-4-week dosing schedule is given at Week 25 |
Dexamethasone should be administered at 40 mg/week (or a reduced dose of 20 mg/week for patients >75 years).
Table 3: DARZALEX dosing schedule in combination with bortezomib, thalidomide and dexamethasone ([VTd]; 4-week cycle dosing regimen) |
||
Treatment phase |
Weeks |
Schedule |
Induction |
Weeks 1 to 8 |
weekly (total of 8 doses) |
Weeks 9 to 16a |
every two weeks (total of 4 doses) |
|
Stop for high dose chemotherapy and ASCT |
||
Consolidation |
Weeks 1 to 8b |
every two weeks (total of 4 doses) |
a First dose of the every-2-week dosing schedule is given at Week 9 b First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT |
Dexamethasone should be administered at 40 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. Dexamethasone 20 mg should be administered on Days 1, 2, 8, 9, 15, 16 in Cycles 5 and 6.
Table 4: DARZALEX dosing schedule in combination with bortezomib and dexamethasone (Vd) (3-week cycle dosing regimen) |
|
Weeks |
Schedule |
Weeks 1 to 9 |
weekly (total of 9 doses) |
Weeks 10 to 24a |
every three weeks (total of 5 doses) |
Week 25 onwards until disease progressionb |
every four weeks |
a First dose of the every-3-week dosing schedule is given at Week 10 b First dose of the every-4-week dosing schedule is given at Week 25 |
Dexamethasone should be administered at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles or a reduced dose of 20 mg/week for patients >75 years, underweight (BMI <18.5), poorly controlled diabetes mellitus or prior intolerance to steroid therapy.
4.8 Undesirable effects
Table 6: Adverse reactions in multiple myeloma patients treated with DARZALEX 16 mg/kg |
||||
System Organ Class |
Adverse reaction |
Frequency |
Incidence (%) |
|
Any Grade |
Grade 3‑4 |
|||
Infections and infestations |
|
Very Common |
|
|
Bronchitisa |
17 |
2 |
||
|
|
|
||
Urinary tract infection |
Common |
8 |
1 |
|
Influenza |
5 |
1* |
||
Sepsisa |
4 |
4 |
||
Cytomegalovirus infectiona |
1 |
<1* |
||
Hepatitis B Virus reactivationb |
Uncommon |
- |
- |
|
Blood and lymphatic system disorders |
Neutropeniaa |
Very Common |
44 |
39 |
Thrombocytopeniaa |
31 |
19 |
||
Anaemiaa |
27 |
12 |
||
Lymphopeniaa |
14 |
11 |
||
Leukopeniaa |
12 |
6 |
||
Immune system disorders |
Anaphylactic reactionb |
Rare |
- |
- |
Metabolism and nutrition disorders |
Decreased appetite |
Very Common |
12 |
1 |
Hyperglycaemia |
Common |
7 |
3 |
|
Hypocalcaemia |
6 |
1 |
||
Dehydration |
3 |
1* |
||
Nervous system disorders |
Peripheral sensory neuropathy |
Very Common
|
32 |
3 |
|
|
<1* |
||
|
|
<1 |
||
Syncope |
Common |
2 |
2* |
|
Cardiac disorders |
Atrial fibrillation |
Common |
4 |
1 |
Vascular disorders |
Hypertensiona |
Very Common |
10 |
5 |
Respiratory, thoracic and mediastinal disorders |
Cougha |
Very Common |
25 |
<1* |
Dyspnoeaa |
21 |
3 |
||
Pulmonary oedemaa |
Common |
1 |
<1 |
|
Gastrointestinal disorders |
|
Very Common |
|
|
|
|
|
||
Nausea |
26 |
2* |
||
Vomiting |
16 |
1* |
||
Pancreatitisa |
Common |
1 |
1 |
|
Musculoskeletal and connective tissue disorders |
Back pain |
Very Common |
18 |
2 |
Muscle spasms |
14 |
<1* |
||
General disorders and administration site conditions |
Fatigue |
Very Common |
26 |
4 |
Oedema peripherala |
26 |
1 |
||
Pyrexia |
23 |
2 |
||
Asthenia |
21 |
2 |
||
Chills |
Common |
9 |
<1* |
|
Injury, poisoning and procedural complications |
Infusion‑related reactionc |
Very Common |
40 |
4 |
* No Grade 4 a Indicates grouping of terms b Post‑marketing adverse reaction c Infusion-related reaction includes terms determined by investigators to be related to infusion, see below |
Updated on 17 June 2021
File name
IRE & NI Darzalex-20 mg _mL_PIL- C13 20 May 21-Clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Free text change information supplied by the pharmaceutical company
Infusion‑related reactions
DARZALEX is given as an infusion (drip) into a vein. Before and after each infusion of DARZALEX, you will be given medicines which help to lower the chance of infusion‑related reactions (see “Medicines given during treatment with DARZALEX” in section 3). These reactions can happen during the infusion or in the 3 days after the infusion.
In some cases you may have a severe allergic reaction which may include a swollen face, lips, mouth, tongue or throat, difficulty swallowing or breathing or an itchy rash (hives). Some serious allergic reactions and other severe infusion-related reactions have resulted in death.
Updated on 17 June 2021
File name
IE&NI_Darzalex 20 mg per mL IV- SmPC C16-047_CLEAN .pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.4 Special warnings and precautions for use
Traceability
In order to improve the traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded.
Infusion‑related reactions
DARZALEX can cause serious IRRs, including anaphylactic reactions (see section 4.8). These reactions can be life-threatening and fatal outcomes have been reported.
Section 4.8
Infections
In patients receiving DARZALEX combination therapy, Grade 3 or 4 infections were reported as follows:
Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 287%, Rd: 23%; DPd: 28%
Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%; D-VTd: 22%, VTd: 20%.
Updated on 13 January 2021
File name
IRE Darzalex-20 mg _mL_PIL- C12 03 Dec 2020-041-Clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 13 January 2021
File name
Darzalex 20 mg per mL IV- SmPC C15-041-Clean-approved.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.8 Undesirable effects
Infections and infestations |
Pneumoniaa |
Very Common |
16 |
10 |
Bronchitisa |
17 |
2 |
||
Upper respiratory tract infectiona |
41 |
3 |
||
Urinary tract infection |
Common |
8 |
1 |
|
Influenza |
5 |
1* |
||
Sepsisa |
4 |
4 |
||
Cytomegalovirus infectiona |
1 |
<1* |
||
Hepatitis B Virus reactivationb |
Uncommon |
- |
- |
Updated on 20 August 2020
File name
IRE Darzalex-20 mg per mL PIL- C11- 20 Jan 2020-038-Clean-approved.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 20 August 2020
File name
Darzalex 20 mg per mL IV- SmPC C14-038-Clean-approved.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.8 Undesirable effects
Summary of the safety profile
The most frequent adverse reactions of any grade (≥20 % patients) with daratumumab (either intravenous or subcutaneous formulations) when administered either as monotherapy or combination treatment were IRRs, fatigue, nausea, diarrhoea, constipation, pyrexia, cough, neutropenia, thrombocytopenia, anaemia, oedema peripheral, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, sepsis, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea and atrial fibrillation.
…………………
System Organ Class |
Adverse reaction |
Frequency |
Incidence (%) |
|
Any Grade |
Grade 3-4 |
|||
Infections and infestations |
Upper respiratory tract infectiona |
Very Common |
38% |
2% |
Bronchitisa |
Very Common |
14% |
2% |
|
Pneumoniaa |
Very Common |
14% |
9% |
|
Urinary tract infection |
Common |
7% |
1% |
|
Influenza |
Common |
4% |
1%# |
|
Sepsisa |
Common |
4% |
3% |
………………………..
Infections
In patients receiving DARZALEX subcutaneous formulation as monotherapy, incidence of infections was similar between DARZALEX subcutaneous formulation (52.9%) versus intravenous daratumumab groups (50.0%). Additionally, Grade 3 or 4 infections also occurred at similar frequencies between DARZALEX subcutaneous formulation (11.7%) and intravenous daratumumab (14.3%). Most infections were manageable and rarely led to treatment discontinuation. Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies.
In patients receiving intravenous daratumumab combination therapy, Grade 3 or 4 infections were reported with intravenous daratumumab combinations and background therapies (as follows:
Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 27%, Rd: 23%; D‑VMP: 23%, VMP: 15%; DPd: 28%
Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%; D‑VTd: 22%, VTd: 20%.).
Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. In active controlled studies, Ddiscontinuations from treatment due to infections were reportedoccurred in 1-4% to 5% of patients. Fatal infections were generally balanced between the intravenous daratumumab containing regimens and active control arms (<2%) in the controlled studies and were primarily due to pneumonia and sepsis.
In patients receiving intravenous daratumumab combination therapy, fatal infections (Grade 5) were reported as follows:
Relapsed/refractory patient studies: DVd: 1%, Vd: 2%; DRd: 2%, Rd: 1%; DPd: 2%
Newly diagnosed patient studies: D-VMP: 1%, VMP: 1%; DRd: 2%, Rd: 2%; DVTd: 0%, VTd: 0%.
Key: D=daratumumab; Vd=bortezomib-dexamethasone; Rd=lenalidomide-dexamethasone; Pd=pomalidomide-dexamethasone; VMP=bortezomib-melphalan-prednisone; VTd=bortezomib-thalidomide-dexamethasone.
………………….
Elderly patients
Of the 3207 patients who received daratumumab (n=490 subcutaneous; n=2717 intravenous) at the recommended dose, 38% were 65 to 75 years of age, and 17% were 75 years of age or older. No overall differences in effectiveness were observed based on age. The incidence of serious adverse reactions was higher in older than in younger patients. Among patients with relapsed and refractory multiple myeloma (n=1827), the most common serious adverse reactions that occurred more frequently in elderly (≥65 years of age) were pneumonia and sepsis. Among patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (n=777), the most common serious adverse reaction that occurred more frequently in elderly (≥75 years of age) was pneumonia.
Updated on 23 July 2020
File name
Darzalex IV- SmPC C13-Clean-11 June 2020.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Immunogenicity
In patients treated with intravenous daratumumab in clinical trials, less than 1% of patients developed treatment-emergent anti-daratumumab antibodies.Patients treated with daratumumab monotherapy (n=199) and combination therapy (n=1051) were evaluated for anti‑therapeutic antibody responses to daratumumab at multiple time points during treatment and up to 8 weeks following the end of treatment. Following the start of daratumumab treatment, none of the monotherapy patients and 2 of the 1051 combination therapy patients tested positive for anti‑daratumumab antibodies; 1 of the combination therapy patients developed transient neutralising antibodies against daratumumab.
However, the employed assay has limitations in detecting anti‑daratumumab antibodies in the presence of high concentrations of daratumumab. Therefore, the incidence of antibody development might not have been reliably determined
Updated on 10 July 2020
File name
Patient Card - Darzalex.pdf
Reasons for updating
- Add New Doc
Updated on 10 July 2020
File name
Darzalex RMP Blood Lab Card June 2020 Update.pdf
Reasons for updating
- Add New Doc
Updated on 10 July 2020
File name
Darzalex RMP HCP Card June 2020.pdf
Reasons for updating
- Add New Doc
Updated on 22 April 2020
File name
C12 SmPC_Darzalex IV-26 March 2020-CLEAN-approved.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
5.1 Pharmacodynamic properties
………….
A total of 706 patients were randomised: 350 to the D-VMP arm and 356 to the VMP arm. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 71 (range: 40-93) years, with 30% of the patients ≥75 years of age. The majority were white (85%), female (54%), 25% had an ECOG performance score of 0, 50% had an ECOG performance score of 1 and 25% had an ECOG performance score of 2. Patients had IgG/IgA/Light chain myeloma in 64%/22%/10% of instances, 19% had ISS Stage I, 42% had ISS Stage II, 38% had ISS Stage III disease and 84% had standard risk cytogenetics. Efficacy was evaluated by PFS based on IMWG criteria and overall survival (OS).
With a median follow‑up of 16.5 months, Tthe primary analysis of PFS in Study MMY3007 showed an improvement in the D-VMP arm as compared to the VMP arm; the median PFS had not been reached in the D-VMP arm and was 18.1 months in the VMP arm (HR=0.5; 95% CI: 0.38, 0.65; p<0.0001)., representing 50% reduction in the risk of disease progression or death in patients treated with D-VMP. Results of an updated PFS analysis approximately 4 months after the original clinical cutoff, continued to show an improvement in PFS for patients in the D-VMP arm compared with the VMP arm. Median PFS was not reached in the D-VMP arm and was 19.3 months in the VMP arm (HR=0.46; 95% CI: 0.36, 0.60; p<0.0001). Results of an updated PFS analysis after a median follow‑up of 40 months continued to show an improvement in PFS for patients in the D‑VMP arm compared with the VMP arm. Median PFS was 36.4 months in the D‑VMP arm and 19.3 months in the VMP arm (HR=0.42; 95% CI: 0.34, 0.51; p<0.0001), representing a 58% reduction in the risk of disease progression or death in patients treated with D‑VMP.
Figure 2: Kaplan-Meier Curve of Primary Analysis of PFS in Study MMY3007
After a median follow‑up of 40 months, D‑VMP has shown an overall survival (OS) advantage over the VMP arm (HR=0.60; 95% CI: 0.46, 0.80; p=0.0003), representing a 40% reduction in the risk of death in patients treated in the D‑VMP arm. Median OS was not reached for either arm.
……………………
With a median follow‑up of 13.5 months, the primary analysis of PFS in Sstudy MMY3003 demonstrated an improvement in PFS in the DRd arm as compared to the Rd arm; the median PFS had not been reached in the DRd arm and was 18.4 months in the Rd arm (HR=0.37; 95% CI: 0.27, 0.52; p<0.0001)., representing 63% reduction in the risk of disease progression or death in patients treated with DRd Results of an updated PFS analysis after a median follow‑up of 55 months continued to show an improvement in PFS for patients in the DRd arm compared with the Rd arm. Median PFS was 45.0 months in the DRd arm and 17.5 months in the Rd arm (HR=0.44; 95% CI: 0.35, 0.54; p<0.0001), representing a 56% reduction in the risk of disease progression or death in patients treated with DRd (see Figure 34).
Figure 34: Kaplan-Meier Curve of PFS in Study MMY3003
……..
Table 11: Additional efficacy results from Study MMY3003 |
||
Response evaluable patient number |
DRd (n=281) |
Rd (n=276) |
Overall response (sCR+CR+VGPR+PR) n(%) |
261 (92.9) |
211 (76.4) |
p-valuea |
< |
|
Stringent complete response (sCR) |
51 (18.1) |
20 (7.2) |
Complete response (CR) |
70 (24.9) |
33 (12.0) |
Very good partial response (VGPR) |
92 (32.7) |
69 (25.0) |
Partial response (PR) |
48 (17.1) |
89 (32.2) |
Median Time to Response [months (95% CI)] |
1.0 (1.0, 1.1) |
1.3 (1.1, 1.9) |
Median Duration of Response [months (95% CI)] |
NE (NE, NE) |
17.4 (17.4, NE) |
MRD negative rate (95% CI) b (%) |
|
|
Odds ratio with 95% CIc |
|
|
P-valued |
< |
|
DRd=daratumumab-lenalidomide-dexamethasone; Rd=lenalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval; NE=not estimable. a p-value from Cochran Mantel-Haenszel Chi-Squared test. b Based on Intent-to-treat population and threshold of 10-4 c d p-value is from a |
………….
With a median follow‑up of 7.4 months, the primary analysis of PFS in Sstudy MMY3004 demonstrated an improvement in PFS in the DVd arm as compared to the Vd arm; the median PFS had not been reached in the DVd arm and was 7.2 months in the Vd arm (HR [95% CI]: 0.39 [0.28, 0.53]; p-value<0.0001), representing a 61% reduction in the risk of disease progression or death for patients treated with DVd versus Vd. Results of an updated PFS analysis after a median follow‑up of 50 months continued to show an improvement in PFS for patients in the DVd arm compared with the Vd arm. Median PFS was 16.7 months in the DVd arm and 7.1 months in the Vd arm (HR [95% CI]: 0.31 [0.24, 0.39]; p-value<0.0001), representing a 69% reduction in the risk of disease progression or death in patients treated with DVd versus Vd (see Figure 45).
Table 12: Additional efficacy results from Study MMY3004 |
||
Response evaluable patient number |
DVd (n=240) |
Vd (n=234) |
Overall response (sCR+CR+VGPR+PR) n(%) |
199 (82.9) |
148 (63.2) |
P-valuea |
< |
|
Stringent complete response (sCR) |
11 (4.6) |
5 (2.1) |
Complete response (CR) |
35 (14.6) |
16 (6.8) |
Very good partial response (VGPR) |
96 (40.0) |
47 (20.1) |
Partial response (PR) |
57 (23.8) |
80 (34.2) |
Median Time to Response [months (range)] |
0.9 (0.8, 1.4) |
1.6 (1.5, 2.1) |
Median Duration of Response [months (95% CI)] |
NE (11.5, NE) |
7.9 (6.7, 11.3) |
MRD negative rate (95% CI)b |
|
|
Odds ratio with 95% CIc |
|
|
P-valued |
|
|
DVd=daratumumab- bortezomib-dexamethasone; Vd=bortezomib-dexamethasone; MRD=minimal residual disease; CI=confidence interval; NE=not estimable. a p-value from Cochran Mantel-Haenszel Chi-Squared test. b Based on Intent-to-treat population and threshold of 10-4 c d p-value is from |
Updated on 22 January 2020
File name
C11 SmPC_Darzalex-20 Jan 2020-030-Clean.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.1 Therapeutic indications
DARZALEX is indicated:
- in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
- in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
- in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
4.2 Posology and method of administration
Dosing schedule in combination with bortezomib, thalidomide and dexamethasone (4-week cycle regimens) for treatment of newly diagnosed patients eligible for autologous stem cell transplant (ASCT):
The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 3.
Table 3: DARZALEX dosing schedule in combination with bortezomib, thalidomide and dexamethasone ([VTd]; 4-week cycle dosing regimen) |
||
Treatment phase |
Weeks |
Schedule |
Induction |
Weeks 1 to 8 |
weekly (total of 8 doses) |
Weeks 9 to 16a |
every two weeks (total of 4 doses) |
|
Stop for high dose chemotherapy and ASCT |
||
Consolidation |
Weeks 1 to 8b |
every two weeks (total of 4 doses) |
a First dose of the every-2-week dosing schedule is given at Week 9 b First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT |
For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.
4.8 Undesirable effects
Summary of the safety profile
The most frequent adverse reactions (≥ 20%) were infusion reactions, fatigue, nausea, diarrhoea, constipation, pyrexia, dyspnoea, cough, back pain, neutropenia, thrombocytopenia, anaemia, oedema peripheral, asthenia, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea and atrial fibrillation.
Tabulated list of adverse reactions
Table 5 6 summarises the adverse drug reactions that occurred in patients receiving DARZALEX. The data reflects exposure to DARZALEX (16 mg/kg) in 1530 2066 patients with multiple myeloma including 1374 1910 patients who received DARZALEX in combination with background regimens and 156 patients who received DARZALEX as monotherapy. Post‑marketing adverse reactions are also included.
In Study MMY3006, the number of CD34+ cell yield was numerically lower in the D-VTd arm compared with the VTd arm (Median: D-VTd: 6.3 x 106/kg; VTd 8.9 x 106/kg) and among those who completed mobilization, more patients in the D-VTd group received plerixafor compared to those in the VTd arm (D-VTd: 21.7%; VTd: 7.9%). The rates of engraftment and haematopoietic reconstitution was similar among the transplanted subjects in the D-VTd and VTd arms (D-VTd: 99.8%; VTd: 99.6%; as measured by the recovery of neutrophils > 0.5 x 109/L, leukocytes > 1.0 x 109/L, and platelets > 50 x 109/L without transfusion).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000). Within each frequency grouping, where relevant, adverse reactions are presented in order of decreasing seriousness.
Table |
||||
System Organ Class |
Adverse reaction |
Frequency |
Incidence (%) |
|
Any Grade |
Grade 3‑4 |
|||
Infections and infestations |
Pneumoniaa |
Very Common |
|
|
Bronchitisa |
|
2 |
||
Upper respiratory tract infectiona |
|
3 |
||
Urinary tract infection |
Common |
|
|
|
Influenza |
5 |
1* |
||
Hepatitis B Virus reactivationb |
Uncommon |
- |
- |
|
Blood and lymphatic system disorders |
Neutropeniaa |
Very Common |
|
|
Thrombocytopeniaa |
|
|
||
Anaemiaa |
|
|
||
Lymphopeniaa |
|
|
||
Leukopeniaa |
|
|
||
Immune system disorders |
Anaphylactic reactionb |
Rare |
- |
- |
Metabolism and nutrition disorders |
Decreased appetite |
Very Common |
|
1 |
Hyperglycemia |
Common |
|
|
|
Hypocalcemia |
|
|
||
Dehydration |
3 |
1* |
||
Nervous system disorders |
Peripheral sensory neuropathy |
Very Common
|
|
3 |
Paraesthesia |
11 |
< 1 |
||
Headache |
|
< 1* |
||
|
|
|
|
|
Cardiac disorders |
Atrial fibrillation |
Common |
4 |
|
Vascular disorders |
Hypertensiona |
Very Common |
|
5 |
Respiratory, thoracic and mediastinal disorders |
Cougha |
Very Common |
|
< 1* |
Dyspnoeaa |
|
3 |
||
Pulmonary oedemaa |
Common |
1 |
<1 |
|
Gastrointestinal disorders |
Diarrhoea |
Very Common |
|
4 |
Constipation |
|
1 |
||
Nausea |
|
|
||
Vomiting |
16 |
1* |
||
Pancreatitisa |
Common |
1 |
1 |
|
Musculoskeletal and connective tissue disorders |
Back pain |
Very Common |
|
2 |
Muscle spasms |
|
< 1* |
||
General disorders and administration site conditions |
Fatigue |
Very Common |
|
|
Oedema peripherala |
|
1 |
||
Pyrexia |
|
|
||
Asthenia |
|
2 |
||
Chills |
Common |
9 |
< 1* |
|
Injury, poisoning and procedural complications |
Infusion‑related reactionc |
Very Common |
|
|
* No Grade 4 a Indicates grouping of terms b Post‑marketing adverse reaction c Infusion-related reaction includes terms determined by investigators to be related to infusion, see below |
Infusion‑related reactions
In clinical trials…….. vomiting and nausea (see section 4.4).
When DARZALEX dosing was interrupted in the setting of ASCT (Study MMY3006) for a median of 3.75 (range: 2.4; 6.9) months, upon re-initiation of DARZALEX the incidence of IRRs was 11% at first infusion following ASCT. Infusion rate/dilution volume used upon re-initiation was that used for the last DARZALEX infusion prior to interruption due to ASCT. IRRs occurring at re-initiation of DARZALEX following ASCT were consistent in terms of symptoms and severity (Grade 3/4: <1%) with those reported in previous studies at Week 2 or subsequent infusions.
….
Infections
In patients receiving DARZALEX combination therapy, Grade 3 or 4 infections were reported as follows:
Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 27%, Rd: 23%; DPd: 28%
Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%; D-VTd: 22%, VTd: 20%.
Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. In the active controlled studies, discontinuations from treatment due to infections (1-4%) and fatal infections were generally infrequent and balanced between the DARZALEX containing regimens and active control arms. Fatal infections were primarily due to pneumonia and sepsis.
Key: D=daratumumab; Vd=bortezomib-dexamethasone; Rd=lenalidomide-dexamethasone; Pd=pomalidomide-dexamethasone; VMP=bortezomib-melphalan-prednisone; VTd=bortezomib-thalidomide-dexamethasone.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Combination treatment with bortezomib, thalidomide and dexamethasone (VTd) in patients eligible for autologous stem cell transplant (ASCT):
Study MMY3006 is a 2 Part, open-label, randomized, active-controlled Phase 3 study. Part 1 compared induction and consolidation treatment with DARZALEX 16 mg/kg in combination with bortezomib, thalidomide and dexamethasone (D-VTd) to treatment with bortezomib, thalidomide and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma eligible for ASCT. The consolidation phase of treatment began a minimum of 30 days post-ASCT, when the patient had recovered sufficiently, and engraftment was complete. In Part 2, subjects with at least a partial response (PR) by Day 100 post-transplant were re-randomized in a 1:1 ratio to daratumumab maintenance or observation only. Only results from Part 1 are described henceforth.
Bortezomib was administered by SC injection or IV injection at a dose of 1.3 mg/m2 body surface area twice weekly for two weeks (Days 1, 4, 8, and 11) of repeated 28 day (4-week) induction treatment cycles (Cycles 1-4) and two consolidation cycles (Cycles 5 and 6) following ASCT after Cycle 4. Thalidomide was administered orally at 100 mg daily during the six bortezomib cycles. Dexamethasone (oral or intravenous) was administered at 40 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. Dexamethasone 20 mg was administered on Days 1, 2, 8, 9, 15, 16 in Cycles 5 and 6. On the days of DARZALEX infusion, the dexamethasone dose was administered intravenously as a pre-infusion medication. Dose adjustments for bortezomib, thalidomide and dexamethasone were applied according to manufacturer’s prescribing information.
A total of 1085 patients were randomized: 543 to the D-VTd arm and 542 to the VTd arm. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 58 (range: 22 to 65) years. All patients were ≤ 65 years: 43% were in the age group ≥ 60-65 years, 41% were in the age group ≥ 50-60 years and 16% below age of 50 years. The majority were male (59%), 48% had an ECOG performance score of 0, 42% had an ECOG performance score of 1 and 10% had an ECOG performance score of 2. Forty percent had International Staging System (ISS) Stage I, 45% had ISS Stage II and 15% had ISS Stage III disease.
Efficacy was evaluated by the stringent Complete Response (sCR) rate at Day 100 post-transplant and Progression free survival (PFS).
Table 9: Efficacy results from Study MMY3006a |
|||
|
D-VTd (n=543) |
VTd (n=542) |
P valueb |
Response assessment Day 100 post-transplant |
|
|
|
Stringent Complete Response (sCR) |
157 (28.9%) |
110 (20.3%) |
0.0010 |
CR or better (sCR+CR) |
211 (38.9%) |
141 (26.0%) |
<0.0001 |
Very Good Partial Response or better (sCR+CR+VGPR) |
453 (83.4%) |
423 (78.0%) |
|
MRD negativityc, d n(%) |
346 (63.7%) |
236 (43.5%) |
<0.0001 |
95% CI (%) |
(59.5%, 67.8%) |
(39.3%, 47.8%) |
|
Odds ratio with 95% CIe |
2.27 (1.78, 2.90) |
|
|
MRD negativity in combination with CR or betterc n(%) |
183 (33.7%) |
108 (19.9%) |
<0.0001 |
95% CI (%) |
(29.7%, 37.9%) |
(16.6%, 23.5%) |
|
Odds ratio with 95% CIe |
2.06 (1.56, 2.72) |
|
|
D-VTd=daratumumab-bortezomib-thalidomide-dexamethasone; VTd=bortezomib-thalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval a Based on intent-to-treat population b p-value from Cochran Mantel-Haenszel Chi-Squared test. c Based on threshold of 10-5 d Regardless of response per IMWG e Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. |
Results of a PFS analysis by censoring patients who were randomized to daratumumab maintenance in the second randomization, at the date of the second randomization showed HR=0.50; 95% CI: 0.34, 0.75; p=0.0005.
4.1 Therapeutic indications
DARZALEX is indicated:
- in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
- in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
- in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
4.2 Posology and method of administration
Dosing schedule in combination with bortezomib, thalidomide and dexamethasone (4-week cycle regimens) for treatment of newly diagnosed patients eligible for autologous stem cell transplant (ASCT):
The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 3.
Table 3: DARZALEX dosing schedule in combination with bortezomib, thalidomide and dexamethasone ([VTd]; 4-week cycle dosing regimen) |
||
Treatment phase |
Weeks |
Schedule |
Induction |
Weeks 1 to 8 |
weekly (total of 8 doses) |
Weeks 9 to 16a |
every two weeks (total of 4 doses) |
|
Stop for high dose chemotherapy and ASCT |
||
Consolidation |
Weeks 1 to 8b |
every two weeks (total of 4 doses) |
a First dose of the every-2-week dosing schedule is given at Week 9 b First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT |
For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.
4.8 Undesirable effects
Summary of the safety profile
The most frequent adverse reactions (≥ 20%) were infusion reactions, fatigue, nausea, diarrhoea, constipation, pyrexia, dyspnoea, cough, back pain, neutropenia, thrombocytopenia, anaemia, oedema peripheral, asthenia, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea and atrial fibrillation.
Tabulated list of adverse reactions
Table 5 6 summarises the adverse drug reactions that occurred in patients receiving DARZALEX. The data reflects exposure to DARZALEX (16 mg/kg) in 1530 2066 patients with multiple myeloma including 1374 1910 patients who received DARZALEX in combination with background regimens and 156 patients who received DARZALEX as monotherapy. Post‑marketing adverse reactions are also included.
In Study MMY3006, the number of CD34+ cell yield was numerically lower in the D-VTd arm compared with the VTd arm (Median: D-VTd: 6.3 x 106/kg; VTd 8.9 x 106/kg) and among those who completed mobilization, more patients in the D-VTd group received plerixafor compared to those in the VTd arm (D-VTd: 21.7%; VTd: 7.9%). The rates of engraftment and haematopoietic reconstitution was similar among the transplanted subjects in the D-VTd and VTd arms (D-VTd: 99.8%; VTd: 99.6%; as measured by the recovery of neutrophils > 0.5 x 109/L, leukocytes > 1.0 x 109/L, and platelets > 50 x 109/L without transfusion).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000). Within each frequency grouping, where relevant, adverse reactions are presented in order of decreasing seriousness.
Table |
||||
System Organ Class |
Adverse reaction |
Frequency |
Incidence (%) |
|
Any Grade |
Grade 3‑4 |
|||
Infections and infestations |
Pneumoniaa |
Very Common |
|
|
Bronchitisa |
|
2 |
||
Upper respiratory tract infectiona |
|
3 |
||
Urinary tract infection |
Common |
|
|
|
Influenza |
5 |
1* |
||
Hepatitis B Virus reactivationb |
Uncommon |
- |
- |
|
Blood and lymphatic system disorders |
Neutropeniaa |
Very Common |
|
|
Thrombocytopeniaa |
|
|
||
Anaemiaa |
|
|
||
Lymphopeniaa |
|
|
||
Leukopeniaa |
|
|
||
Immune system disorders |
Anaphylactic reactionb |
Rare |
- |
- |
Metabolism and nutrition disorders |
Decreased appetite |
Very Common |
|
1 |
Hyperglycemia |
Common |
|
|
|
Hypocalcemia |
|
|
||
Dehydration |
3 |
1* |
||
Nervous system disorders |
Peripheral sensory neuropathy |
Very Common
|
|
3 |
Paraesthesia |
11 |
< 1 |
||
Headache |
|
< 1* |
||
|
|
|
|
|
Cardiac disorders |
Atrial fibrillation |
Common |
4 |
|
Vascular disorders |
Hypertensiona |
Very Common |
|
5 |
Respiratory, thoracic and mediastinal disorders |
Cougha |
Very Common |
|
< 1* |
Dyspnoeaa |
|
3 |
||
Pulmonary oedemaa |
Common |
1 |
<1 |
|
Gastrointestinal disorders |
Diarrhoea |
Very Common |
|
4 |
Constipation |
|
1 |
||
Nausea |
|
|
||
Vomiting |
16 |
1* |
||
Pancreatitisa |
Common |
1 |
1 |
|
Musculoskeletal and connective tissue disorders |
Back pain |
Very Common |
|
2 |
Muscle spasms |
|
< 1* |
||
General disorders and administration site conditions |
Fatigue |
Very Common |
|
|
Oedema peripherala |
|
1 |
||
Pyrexia |
|
|
||
Asthenia |
|
2 |
||
Chills |
Common |
9 |
< 1* |
|
Injury, poisoning and procedural complications |
Infusion‑related reactionc |
Very Common |
|
|
* No Grade 4 a Indicates grouping of terms b Post‑marketing adverse reaction c Infusion-related reaction includes terms determined by investigators to be related to infusion, see below |
Infusion‑related reactions
In clinical trials…….. vomiting and nausea (see section 4.4).
When DARZALEX dosing was interrupted in the setting of ASCT (Study MMY3006) for a median of 3.75 (range: 2.4; 6.9) months, upon re-initiation of DARZALEX the incidence of IRRs was 11% at first infusion following ASCT. Infusion rate/dilution volume used upon re-initiation was that used for the last DARZALEX infusion prior to interruption due to ASCT. IRRs occurring at re-initiation of DARZALEX following ASCT were consistent in terms of symptoms and severity (Grade 3/4: <1%) with those reported in previous studies at Week 2 or subsequent infusions.
….
Infections
In patients receiving DARZALEX combination therapy, Grade 3 or 4 infections were reported as follows:
Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 27%, Rd: 23%; DPd: 28%
Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%; D-VTd: 22%, VTd: 20%.
Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. In the active controlled studies, discontinuations from treatment due to infections (1-4%) and fatal infections were generally infrequent and balanced between the DARZALEX containing regimens and active control arms. Fatal infections were primarily due to pneumonia and sepsis.
Key: D=daratumumab; Vd=bortezomib-dexamethasone; Rd=lenalidomide-dexamethasone; Pd=pomalidomide-dexamethasone; VMP=bortezomib-melphalan-prednisone; VTd=bortezomib-thalidomide-dexamethasone.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Combination treatment with bortezomib, thalidomide and dexamethasone (VTd) in patients eligible for autologous stem cell transplant (ASCT):
Study MMY3006 is a 2 Part, open-label, randomized, active-controlled Phase 3 study. Part 1 compared induction and consolidation treatment with DARZALEX 16 mg/kg in combination with bortezomib, thalidomide and dexamethasone (D-VTd) to treatment with bortezomib, thalidomide and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma eligible for ASCT. The consolidation phase of treatment began a minimum of 30 days post-ASCT, when the patient had recovered sufficiently, and engraftment was complete. In Part 2, subjects with at least a partial response (PR) by Day 100 post-transplant were re-randomized in a 1:1 ratio to daratumumab maintenance or observation only. Only results from Part 1 are described henceforth.
Bortezomib was administered by SC injection or IV injection at a dose of 1.3 mg/m2 body surface area twice weekly for two weeks (Days 1, 4, 8, and 11) of repeated 28 day (4-week) induction treatment cycles (Cycles 1-4) and two consolidation cycles (Cycles 5 and 6) following ASCT after Cycle 4. Thalidomide was administered orally at 100 mg daily during the six bortezomib cycles. Dexamethasone (oral or intravenous) was administered at 40 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. Dexamethasone 20 mg was administered on Days 1, 2, 8, 9, 15, 16 in Cycles 5 and 6. On the days of DARZALEX infusion, the dexamethasone dose was administered intravenously as a pre-infusion medication. Dose adjustments for bortezomib, thalidomide and dexamethasone were applied according to manufacturer’s prescribing information.
A total of 1085 patients were randomized: 543 to the D-VTd arm and 542 to the VTd arm. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 58 (range: 22 to 65) years. All patients were ≤ 65 years: 43% were in the age group ≥ 60-65 years, 41% were in the age group ≥ 50-60 years and 16% below age of 50 years. The majority were male (59%), 48% had an ECOG performance score of 0, 42% had an ECOG performance score of 1 and 10% had an ECOG performance score of 2. Forty percent had International Staging System (ISS) Stage I, 45% had ISS Stage II and 15% had ISS Stage III disease.
Efficacy was evaluated by the stringent Complete Response (sCR) rate at Day 100 post-transplant and Progression free survival (PFS).
Table 9: Efficacy results from Study MMY3006a |
|||
|
D-VTd (n=543) |
VTd (n=542) |
P valueb |
Response assessment Day 100 post-transplant |
|
|
|
Stringent Complete Response (sCR) |
157 (28.9%) |
110 (20.3%) |
0.0010 |
CR or better (sCR+CR) |
211 (38.9%) |
141 (26.0%) |
<0.0001 |
Very Good Partial Response or better (sCR+CR+VGPR) |
453 (83.4%) |
423 (78.0%) |
|
MRD negativityc, d n(%) |
346 (63.7%) |
236 (43.5%) |
<0.0001 |
95% CI (%) |
(59.5%, 67.8%) |
(39.3%, 47.8%) |
|
Odds ratio with 95% CIe |
2.27 (1.78, 2.90) |
|
|
MRD negativity in combination with CR or betterc n(%) |
183 (33.7%) |
108 (19.9%) |
<0.0001 |
95% CI (%) |
(29.7%, 37.9%) |
(16.6%, 23.5%) |
|
Odds ratio with 95% CIe |
2.06 (1.56, 2.72) |
|
|
D-VTd=daratumumab-bortezomib-thalidomide-dexamethasone; VTd=bortezomib-thalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval a Based on intent-to-treat population b p-value from Cochran Mantel-Haenszel Chi-Squared test. c Based on threshold of 10-5 d Regardless of response per IMWG e Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. |
Results of a PFS analysis by censoring patients who were randomized to daratumumab maintenance in the second randomization, at the date of the second randomization showed HR=0.50; 95% CI: 0.34, 0.75; p=0.0005.
Updated on 22 January 2020
File name
IRE C10 PIL-Darzalex- 20 Jan 2020-030-Clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 20 November 2019
File name
IRE C09 PIL-Darzalex- 19 Nov2019-Clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 20 November 2019
File name
C10 SmPC-Darzalex- 19 Nov2019-029-Clean.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.1 Therapeutic indications
DARZALEX is indicated:
- in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.- in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
4.2 Posology and method of administration
DARZALEX should be administered by a healthcare professional, in an environment where resuscitation facilities are available.
Pre‑ and post‑infusion medications should be administered to reduce the risk of infusion‑related reactions (IRRs) with daratumumab. See below “Recommended concomitant medications”, “Management of infusion‑related reactions” and section 4.4.
Posology
Dosing schedule in combination with lenalidomide (4‑week cycle regimen) and for monotherapy:
The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 1.
Table 1: DARZALEX dosing schedule in combination with lenalidomide (4-week cycle dosing regimen) and monotherapy |
|
Weeks |
Schedule |
Weeks 1 to 8 |
weekly (total of 8 doses) |
Weeks 9 to 24a |
every two weeks (total of 8 doses) |
Week 25 onwards until disease progressionb |
every four weeks |
a First dose of the every-2-week dosing schedule is given at Week 9 b First dose of the every-4-week dosing schedule is given at Week 25 |
For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.
Newly diagnosed multiple myeloma
Dosing schedule in combination with bortezomib, melphalan and prednisone (6-week cycle regimens) :for patients ineligible for autologous stem cell transplant
The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 2.1
Table |
|
Weeks |
Schedule |
Weeks 1 to 6 |
weekly (total of 6 doses) |
Weeks 7 to 54a |
every three weeks (total of 16 doses) |
Week 55 onwards until disease progressionb |
every four weeks |
a First dose of the every-3-week dosing schedule is given at Week 7 b First dose of the every-4-week dosing schedule is given at Week 55 |
Bortezomib is given twice weekly at Weeks 1, 2, 4 and 5 for the first 6-week cycle, followed by once weekly at Weeks 1, 2, 4 and 5 for eight more 6-week cycles. For information on the VMP dose and dosing schedule when administered with DARZALEX, see section 5.1.
Relapsed/Refractory multiple myeloma
Dosing schedule for monotherapy and in combination with lenalidomide (4‑week cycle regimen):
The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 2.
|
|
|
|
|
|
|
|
|
|
|
For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.
4.5 Interaction with other medicinal products and other forms of interaction
……
Clinical pharmacokinetic assessments of daratumumab in combination with lenalidomide, pomalidomide, thalidomide, bortezomib and dexamethasone indicated no clinically-relevant drug-drug interaction between DARZALEX and these and small molecule medicinal products.combination therapies
4.8 Undesirable effects
Summary of the safety profile
The most frequent adverse reactions (≥ 20%) were infusion reactions, fatigue, nausea, diarrhoea, constipation, pyrexia, dyspnoea, cough, back pain, neutropenia, thrombocytopenia, anaemia, oedema peripheral, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea and atrial fibrillation.muscle spasms
Tabulated list of adverse reactions
Table 5 summarises the adverse drug reactions that occurred in patients receiving DARZALEX. The data reflects exposure to DARZALEX (16 mg/kg) in 1530 patients with multiple myeloma including 1374 patients who received DARZALEX in combination with background regimens and 156 patients who received DARZALEX as monotherapy. Post‑marketing adverse reactions are also included. 1166 patients with multiple myeloma including 872 patients from three Phase III active-controlled trials who received DARZALEX in combination with either lenalidomide and dexamethasone (DRd; n=283; Study MMY3003), bortezomib and dexamethasone (DVd; n=243; Study MMY3004), or bortezomib, melphalan and prednisone (D‑VMP, n=346; Study MMY3007), and five open-label, clinical trials in which patients received DARZALEX either in combination with pomalidomide and dexamethasone (DPd; n=103), in combination with lenalidomide and dexamethasone (n=35) or as monotherapy (n=156)
Table 5: Adverse reactions in multiple myeloma patients treated with DARZALEX 16 mg/kg |
||||
System Organ Class |
Adverse reaction |
Frequency |
Incidence (%) |
|
Any Grade |
Grade 3‑4 |
|||
Infections and infestations |
Pneumoniaa |
Very Common |
|
|
Bronchitisa |
16 |
2 |
||
Upper respiratory tract infectiona |
|
|
||
Urinary tract infection |
Common |
9 |
2 |
|
Influenza |
5 |
1* |
||
|
|
|
|
|
Hepatitis B Virus reactivationb |
Uncommon |
- |
- |
|
Blood and lymphatic system disorders |
Neutropeniaa |
Very Common |
|
|
Thrombocytopeniaa |
|
|
||
Anaemiaa |
|
|
||
Lymphopeniaa |
|
|
||
Leukopeniaa |
14 |
8 |
||
Immune system disorders |
Anaphylactic reactionb |
Rare |
- |
- |
Metabolism and nutrition disorders |
Decreased appetite |
Very Common |
14 |
1* |
Hyperglycemia |
Common |
9 |
4 |
|
Hypocalcemia |
7 |
2 |
||
Dehydration |
3 |
1* |
||
Nervous system disorders |
Peripheral sensory neuropathy |
Very Common
|
|
2 |
Headache |
|
< 1* |
||
Paraesthesia |
Common |
7 |
< 1 |
|
Cardiac disorders |
Atrial fibrillation |
Common |
4 |
|
Vascular disorders |
Hypertensiona |
Very Common |
|
5 |
Respiratory, thoracic and mediastinal disorders |
Cougha |
Very Common |
|
< 1* |
Dyspnoeaa |
|
3 |
||
Pulmonary oedemaa |
Common |
1 |
1 |
|
Gastrointestinal disorders |
Diarrhoea |
Very Common |
|
|
Constipation |
27 |
1 |
||
Nausea |
|
1* |
||
Vomiting |
|
1* |
||
Musculoskeletal and connective tissue disorders |
Back pain |
Very Common |
21 |
2 |
Muscle spasms |
|
< 1* |
||
General disorders and administration site conditions |
Fatigue |
Very Common |
31 |
5 |
Oedema peripherala |
25 |
1 |
||
Pyrexia |
21 |
1* |
||
Asthenia |
17 |
2 |
||
Chills |
Common |
9 |
< 1* |
|
|
|
|
|
|
|
|
|
||
|
|
|
||
Injury, poisoning and procedural complications |
Infusion‑related reactionc |
Very Common |
|
5 |
* No Grade 4 a Indicates grouping of terms b Post‑marketing adverse reaction c Infusion-related reaction includes terms determined by investigators to be related to infusion, see below |
Infusion‑related reactions
In clinical trials (monotherapy and combination treatments; N=1530) the incidence of any grade infusion‑related reactions was 40% with the first (16 mg/kg, Week 1) infusion of DARZALEX, 2% with the Week 2 infusion, and cumulatively 4% with subsequent infusions. Less than 1% of patients had a Grade 3/4 infusion‑related reaction with the Week 2 or subsequent infusions. 1166Grade 4 infusion reactions were reported in 2/1166 (0.2%) of patients.
The median time to onset of a reaction was 1.5 hours (range: 0 to 72.8 hours). The incidence of infusion modifications due to reactions was 37%. Median durations of 16 mg/kg infusions for the 1st Week, 2nd Week and subsequent infusions were approximately 7, 4 4 and 3.3 hours respectively..4
Severe infusion‑related reactions included bronchospasm, dyspnoea, laryngeal oedema, pulmonary oedema, hypoxia, and hypertension. Other adverse infusion‑related reactions included nasal congestion, cough, chills, throat irritation, vomiting and nausea (see section 4.4).
…….
Infections
In patients receiving DARZALEX combination therapy, Grade 3 or 4 infections were reported with DARZALEX combinations and background therapies as follows: (
Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 27%, Rd: 23%; DPd: 28%D‑VMP:23%, VMP:15%; )
Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%.
Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. In the active controlled studies, discontinuations from treatment due to infections (1-4%) Discontinuations from treatment due to infections were reported in 1% to 5% of patients. and fatal infections were generally infrequent and balanced between the DARZALEX containing regimens and active control arms. F(<2%) in the controlled studiesFatal infections were primarily due to pneumonia and sepsis and
5.1 Pharmacodynamic properties
Immunogenicity
Patients treated with daratumumab monotherapy (n=199) and combination therapy (n=750) were evaluated for anti‑therapeutic antibody responses to daratumumab at multiple time points during treatment and up to 8 weeks following the end of treatment. Following the start of daratumumab treatment, none of the monotherapy patients and 2 of the 412750 combination therapy patients tested.412
Clinical efficacy and safety
Newly diagnosed multiple myeloma
Combination treatment with lenalidomide and dexamethasone in patients ineligible for autologous stem cell transplant:
Study MMY3008, an open-label, randomized, active-controlled Phase III study, compared treatment with DARZALEX 16 mg/kg in combination with lenalidomide and low-dose dexamethasone (DRd) to treatment with lenalidomide and low-dose dexamethasone (Rd) in patients with newly diagnosed multiple myeloma. Lenalidomide (25 mg once daily orally on Days 1-21 of repeated 28-day [4-week] cycles) was given with low dose oral or intravenous dexamethasone 40 mg/week (or a reduced dose of 20 mg/week for patients >75 years or body mass index [BMI] <18.5). On DARZALEX infusion days, the dexamethasone dose was given as a pre-infusion medication. Dose adjustments for lenalidomide and dexamethasone were applied according to manufacturer’s prescribing information. Treatment was continued in both arms until disease progression or unacceptable toxicity.
A total of 737 patients were randomized: 368 to the DRd arm and 369 to the Rd arm. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 73 (range: 45-90) years, with 44% of the patients ≥75 years of age. The majority were white (92%), male (52%), 34% had an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 49.5% had an ECOG performance score of 1 and 17% had an ECOG performance score of ≥2. Twenty-seven percent had International Staging System (ISS) Stage I, 43% had ISS Stage II and 29% had ISS Stage III disease. Efficacy was evaluated by progression free survival (PFS) based on International Myeloma Working Group (IMWG) criteria.
Study MMY3008 showed an improvement in Progression Free Survival (PFS) in the DRd arm as compared to the Rd arm; the median PFS had not been reached in the DRd arm and was 31.9 months in the Rd arm (hazard ratio [HR]=0.56; 95% CI: 0.43, 0.73; p<0.0001), representing 44% reduction in the risk of disease progression or death in patients treated with DRd. Results of an updated PFS analysis approximately 9 months after the original clinical cutoff, continued to show an improvement in PFS for patients in the DRd arm compared with the Rd arm. Median PFS was not reached in the DRd arm and was 33.8 months in the Rd arm (HR=0.56; 95% CI: 0.44, 0.71; p<0.0001).
Figure 1: Kaplan-Meier Curve of PFS in Study MMY3008
Additional efficacy results from Study MMY3008 are presented in Table 6 below.
Table 6: Additional efficacy results from Study MMY3008a |
||
|
DRd (n=368) |
Rd (n=369) |
Overall response (sCR+CR+VGPR+PR) n(%)a |
342 (92.9%) |
300 (81.3%) |
p-valueb |
<0.0001 |
|
Stringent complete response (sCR) |
112 (30.4%) |
46 (12.5%) |
Complete response (CR) |
63 (17.1%) |
46 (12.5%) |
Very good partial response (VGPR) |
117 (31.8%) |
104 (28.2%) |
Partial response (PR) |
50 (13.6%) |
104 (28.2%) |
CR or better (sCR + CR) |
175 (47.6%) |
92 (24.9%) |
p-valueb |
<0.0001 |
|
VGPR or better (sCR + CR + VGPR) |
292 (79.3%) |
196 (53.1%) |
p-valueb |
<0.0001 |
|
MRD negativity ratea,c n(%) |
89 (24.2%) |
27 (7.3%) |
95% CI (%) |
(19.9%, 28.9%) |
(4.9%, 10.5%) |
Odds ratio with 95% CId |
4.04 (2.55, 6.39) |
|
p-valuee |
<0.0001 |
|
DRd=daratumumab-lenalidomide-dexamethasone; Rd=lenalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval a Based on intent-to-treat population b p-value from Cochran Mantel-Haenszel Chi-Squared test. c Based on threshold of 10-5 d Mantel-Haenszel estimate of the odds ratio for un-stratified tables is used. An odds ratio > 1 indicates an advantage for DRd. e p-value from Fisherʼs exact test. |
In responders, the median time to response was 1.05 months (range: 0.2 to 12.1 months) in the DRd group and 1.05 months (range: 0.3 to 15.3 months) in the Rd group. The median duration of response had not been reached in the DRd group and was 34.7 months (95% CI: 30.8, not estimable) in the Rd group.
5.2 Pharmacokinetic properties
Four population PK analyses were performed to describe the PK characteristics of daratumumab and to evaluate the influence of covariates on the disposition of daratumumab in patients with multiple myeloma; Analysis 1 (n=223) in patients receiving DARZALEX monotherapy while Analysis 2 (n=694),Three Analysis 3 (n=352) and Analysis 4 (n=355) were conducted in patients with multiple myeloma that received daratumumab combination therapies. Analysis 2 included 694 patients (n=326 for lenalidomide-dexamethasone; n=246 for bortezomib-dexamethasone; n=99 for pomalidomide-dexamethasone; n=11 for bortezomib-melphalan-prednisone; and n=12 for bortezomib-thalidomide-dexamethasone), and Analysis 3 included 352 patients (bortezomib‑melphalan‑prednisone) and Analysis 4 included 355 patients (lenalidomide-dexamethasone). and
Three additional population PK analyses (Analysis 2Two , Analysis 3 and Analysis 4) were conducted in patients with multiple myeloma that received daratumumab combination therapies. Daratumumab concentration‑time profiles were similar following the monotherapy and combination therapies. The mean estimated terminal half-life associated with linear clearance in combination therapy was approximately and15‑23 days.22
Based on the four population PK analyses (Analyses 1-three 4) body weight was identified as a statistically significant covariate for daratumumab clearance. Therefore, body weight based dosing is an appropriate dosing strategy for the multiple myeloma patients.3
Special populations
Age and gender
Based on four individual population PK analyses (1-three 4) in patients receiving daratumumab monotherapy or various combination therapies (Analyses 1-34), age (range: 31‑93 years) had no clinically important effect on the PK of daratumumab, and the exposure of daratumumab was similar between younger (aged <65 years, n=3518) and older (aged ≥65 to <75 years n=515761; aged ≥75 years, n=562334) patients.181
……
Renal impairment
No formal studies of daratumumab in patients with renal impairment have been conducted. Four individual population PK analyses were performed based on pre‑existing renal function data in patients receiving daratumumab monotherapy, or various combination therapies (Analyses 1-Three 4), and included a total of 3441 patients with normal renal function (creatinine clearance [CRCL] ≥90 mL/min), 381 621 with mild renal impairment (CRCL <90 and ≥60 mL/min), 480 523 with moderate renal impairment (CRCL <60 and ≥30 mL/min), and 376 27 with severe renal impairment or end stage renal disease (CRCL<30 mL/min). No clinically important differences in exposure to daratumumab were observed between patients with renal impairment and those with normal renal function.20
Hepatic impairment
No formal studies of daratumumab in patients with hepatic impairment have been conducted. Changes in hepatic function are unlikely to have any effect on the elimination of daratumumab since IgG1 molecules such as daratumumab are not metabolised through hepatic pathways.
Four individual population PK analyses were performed in patients receiving daratumumab monotherapy or various combination therapies (Analyses 1-Three 4), and included a total of 31404 patients with normal hepatic function (total bilirubin [TB] and aspartate aminotransferase [AST] ≤ upper limit of normal [ULN]), 1081 189 with mild hepatic impairment (TB 1.0 x to 1.5 x ULN or AST >ULN) and 159 8 patients with moderate (TB > 1.5 x to 3.0 x ULN; n=7 7), or severe (TB > 3.0 x ULN; n=1) hepatic impairment. No clinically important differences in the exposure to daratumumab were observed between patients with hepatic impairment and those with normal hepatic function.6
Race
Based on four individual population PK analyses in patients receiving either daratumumab monotherapy or various combination therapies (Analyses 1-three 4), the exposure to daratumumab was similar between white (n=31371) and non‑white subjects (n=1046242).212
Updated on 02 July 2019
File name
IRE -C08-PIL-Darzalex- Jun 2019-CLEAN.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 02 July 2019
File name
C09_SmPC-Darzalex-28 June 2019_Clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.4 Special warnings and precautions for use
Hepatitis B virus (HBV) Reactivation
Hepatitis B virus reactivation, in some cases fatal, has been reported in patients treated with DARZALEX. HBV screening should be performed in all patients before initiation of treatment with DARZALEX.
For patients with evidence of positive HBV serology, monitor for clinical and laboratory signs of HBV reactivation during, and for at least six months following the end of DARZALEX treatment. Manage patients according to current clinical guidelines. Consider consulting a hepatitis disease expert as clinically indicated.
In patients who develop reactivation of HBV while on DARZALEX, suspend treatment with DARZALEX and institute appropriate treatment. Resumption of DARZALEX treatment in patients whose HBV reactivation is adequately controlled should be discussed with physicians with expertise in managing HBV.
4.8 Undesirable effects
Infections and infestations |
Pneumoniaa |
Very Common |
16 |
11 |
Upper respiratory tract infectiona |
50 |
5 |
||
Influenza |
Common |
4 |
1* |
|
Hepatitis B Virus reactivationb |
Uncommon |
- |
- |
Updated on 21 December 2018
File name
IRE C07-PIL-Darzalex-Dec 2018-clean.pdf
Reasons for updating
- Change to section 3 - dose and frequency
- Change to section 6 - date of revision
Updated on 21 December 2018
File name
C08_SmPC-Darzalex-18 December 2018-clean.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 10 December 2018
File name
IRE C06-PIL-Darzalex-Nov 2018-clean.pdf
Reasons for updating
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Updated on 10 December 2018
File name
C07_SmPC-Darzalex-30 November 2018-Clean.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
6.5 Nature and contents of container
5 mL concentrate in a Type 1 glass vial with an elastomeric closure and an aluminium seal with a flip‑off button containing 100 mg of daratumumab. Pack size of 1 vial.
20 mL concentrate in a Type 1 glass vial with an elastomeric closure and an aluminium seal with a flip‑off button containing 400 mg of daratumumab. Pack size of 1 vial.
DARZALEX is also supplied as an initiation pack containing 11 vials : (6 x 5 mL vials + 5 x 20 mL vials).
8. MARKETING AUTHORISATION NUMBER(S)
EU/1/16/1101/001
EU/1/16/1101/002
EU/1/16/1101/003
Updated on 30 October 2018
File name
IRE C05-PIL-Darzalex-Oct 2018-CLEAN.pdf
Reasons for updating
- Change to section 6 - date of revision
- Change of distributor details
Updated on 04 September 2018
File name
C04-PIL-Darzalex-Aug 2018-Clean.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 3 - duration of treatment
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 04 September 2018
File name
C06_SmPC-Darzalex-31 August 2018.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Addition 4.2 Posology and method of administrationof a new indication.
DARZALEX is indicated:
- in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
4.2 Posology and method of administration
This section has been extensively revised
Section 4.8
Added. very common , hu ypertension Common: pulmonary oedema
Section 5.1 and 5.2 updated
Updated on 28 June 2018
File name
C05_SmPC_Darzalex_03_May_18-CLEAN_approved.docx
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Unforunately the is section will not allow all the changes to be published. Please conatc Janssen-Cilag Ltd medical informatiomn if you would like the details of the changes
Updated on 28 June 2018
File name
C03-PIL-Darzalex- TC- May 2018_Clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Change to information for healthcare professionals
Updated on 16 May 2018
File name
C04_SmPC_Darzalex_15_Mar_18_Clean.docx
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 16 August 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 16 August 2017
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
6.3 Shelf life
Unopened vials
Updated on 16 August 2017
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
6.3 Shelf life
Unopened vials
Updated on 03 May 2017
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.1 Therapeutic indications
DARZALEX is indicated:
· as monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
· in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone,for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
4.2 Posology and method of administration
Dose
Standard dosing for monotherapy and in combination with lenalidomide (4‑week cycle regimen):
The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 1.:
Table 1: Standard DARZALEX dosing schedule for monotherapy and in combination with lenalidomide (4-week cycle dosing regimen) |
|
Weeks |
Schedule |
Weeks 1 to 8 |
weekly (total of 8 doses) |
Weeks 9 to 24a |
every two weeks (total of 8 doses) |
Week 25 onwards until disease progressionb |
every four weeks |
a First dose of the every-2-week dosing schedule is given at week 9 b First dose of the every-4-week dosing schedule is given at week 25
|
For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.
Modified dosing schedule in combination with bortezomib (3‑week cycle regimen):
The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 2.
Table 2: Modified DARZALEX dosing schedule in combination with bortezomib (3-week cycle dosing regimen) |
|
Weeks |